Ecovyst Q3 Sales Reach $308.6 Million, Above IBES Estimate
Ecovyst reported Q3 sales of USD 308.6 million versus the IBES estimate of USD 284.4 million.
Related stories
Moderna Q3 Earnings
Rev: $1.31B (est $888.1M) - EPS: 38c (est loss/shr $1.09) - R&D Expenses: $583M (est $750M) - Total Operating Expenses: $1.18B (est $1.37B) - Cash & Cash Equivalents: $1.20B (est $
H impact | EARNINGS | Nov 06, 2026, 11:57 AM UTC
EDP Reports 9-Month Net Profit of €1.194 Billion
EDP said net profit rose from €952 million a year earlier. Recurring net profit increased 22% to €1.191 billion, and recurring EBITDA rose 11% to €4.166 billion.
M impact | EARNINGS | Nov 06, 2026, 11:48 AM UTC
Airsculpt Technologies reports Q3 adjusted EBITDA of $400,000
Reuters also reports Q3 net income of -$7.2 million.
M impact | EARNINGS | Nov 06, 2026, 11:46 AM UTC
Telus Reports Q3 Net Income of CAD -660 Million
Telus reported Q3 adjusted net income of CAD 251 million.
M impact | EARNINGS | Nov 06, 2026, 11:46 AM UTC
Moderna reports Q3 EPS of USD 0.38
Moderna reported Q3 net income of USD 162 million.
M impact | EARNINGS | Nov 06, 2026, 11:46 AM UTC
Moderna Raises Year-End 2026 Cash and Investments Outlook
Moderna now expects year-end 2026 cash and investments of about $8.1B-$8.3B, versus its prior view of $4.7B-$5.2B.
M impact | EARNINGS | Nov 06, 2026, 11:45 AM UTC